Abstract
Post-transplant lymphoproliferative disorder is a fatal complication that can occur early after solid organ or hematopoietic stem cell transplantation (HSCT). It represents a spectrum of Epstein Barr virus (EBV)-related clinical diseases, from benign mononucleosis like illness to malignancies like non-Hodgkin's lymphoma. Some of the established risk factors for PTLD are HLA mismatching, T-cell depletion, and the use of anti-lymphocyte antibodies as conditioning or immunosuppression for the treatment of graft-versus-host disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
